Decoding the Vaginal Microbiome

Privately held Aprecia Pharmaceuticals, LLC (Aprecia) and CMIC CMO Co., LTD (CMIC CMO) today announced that both companies will collaborate to develop business opportunities in Japan for Aprecias ZipDoseTechnology. CMIC CMOs services will include identifying prospects in Japan, generating awareness and facilitating discussions of technology licensing agreements, research collaborations and distribution partnerships. Through this engagement Aprecia seeks to expand its 3DP products globally, and this agreement highlights the importance of Japan in its long term strategy.

To slow or reverse the effects of climate change, there is promise in development of biotechnology innovations that enhance the adaptation, resilience, preservation, and restoration of natural and managed ecosystems.

The genetic medicine revolution is truly underway. The COVID-19 pandemic has allowed mRNA and DNA-based vaccines to show their true potential, but the industry has ongoing challenges to overcome. Almost all of today’s genetic medicines (mRNA, DNA vaccines, viral vectors) are dependent on plasmid DNA as either a critical starting material or API, which presents challenges in advanced therapy manufacturing. Although plasmid DNA has proven its worth, enabling the production and availability of vaccines, there is also a bottleneck in the industry with contract manufacturers who offer GMP quality plasmid DNA, resulting in a substantial supply restriction. The inability to provide quality DNA within tight timelines is a threat to the rapid progress of R&D pipelines. Moreover, antibiotic resistance genes in plasmid DNA are becoming a crucial global issue and a topic of increasing regulatory scrutiny.

This webinar will give you sufficient understanding to classify new products and technologies containing human tissues or cells and to understand the impact of such products in a portfolio.